Recent Updates
Recently added Catalysts

ARV-471 in combination with Everolimus

Phase 2

Breast Cancer | Small Molecules | Oncology |Arvinas, Inc.|Trials Updated: Sep 26, 2025

ARV-471 in combination with Everolimus development status

Highest phase Phase 2
Registered trials 1 across 1 sponsor since Aug 2022

ARV-471 in combination with Everolimus target and mechanism

Molecular targetER
Target classReceptor
ModalitySmall Molecules

Also known as ARV-471

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDBiomarker
Total Trials2
Total Enrollment184

FDA Designations

No designations recorded

ARV-471 in combination with Everolimus clinical trials

ARV-471 in combination with Everolimus · 2 trials · 1 indication

Phase 2 1Phase 1 1
NCT05549505A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryBreast Cancer
COMPLETED152 Analytics
PHASE2COMPLETED
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Breast CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Percent Reduction in Ki-67 Expression From Baseline to Day 15 in Tumor Biopsies
Baseline (during screening, prior to Day 1) and Day 15

Tumor biopsy Ki-67 expression (% of tumor cells that are positive for Ki-67) at baseline and Cycle 1 Day 15 (C1D15) was collected. Ki-67 expression was assessed by immunohistochemical staining in a central laboratory. The log-transformed Ki-67 after approximately 2 weeks of treatment as a percentage of the baseline value, ie, the ratio between the Ki-67 measurements obtained from C1D15 visit and baseline was modelled using a generalized linear model (GLM) with both stratification factors (ie, baseline Ki-67 score and the tumor size) and treatment as co-variates. The treatment effects were back transformed into geometric means and their Confidence Intervals. The percent change, in other words, relative reduction, of Ki-67 after 2 weeks of treatment is reported as the complement of the ratio between the Ki-67 measurement from C1D15 and baseline, that is 100% × (1 - geometric mean ratio between Ki-67 at C1D15 and Ki-67 at baseline).

Incidence of dose limiting toxicities of ARV-471 in combination with everolimus
35 Days

Dose limiting toxicities in the first 35 days of the study combination treatment characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study drug

Recommended Phase 2 Dose (RP2D) for ARV-471 in combination with everolimus
35 Days
Number of participants with adverse events as a measure of safety and tolerability of ARV-471 in combination with everolimus
28 calendar days after participant discontinues study treatment

Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug combination

Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471 in combination with everolimus
28 calendar days after participant discontinues study treatment

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing

Secondary Endpoints

Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Study Drug Discontinuation
From signing of consent to minimum of 30 days after last administration of study drug (up to approximately 6.5 months)
Pathologic Stage at the Time of Surgical Resection
At Cycle 6 Day 18 (approximately 5.5 months), each cycle is 28 days
Pathological Complete Response(pCR) Rate at the Time of Surgical Resection
At Cycle 6 Day 18 (approximately 5.5 months), each cycle is 28 days
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A: ARV-471 (Experimental)EXPERIMENTALParticipants received 200 mg ARV-471 (2\*100 mg tablets) once daily for approximately 5.5 months prior to undergoing surgical resection (no later than Cycle 6 Day 18 \[C6D18\] + 14 days).
Arm B: AnastrozoleACTIVE_COMPARATORParticipants received 1 mg Anastrozole tablet orally once daily for approximately 5.5 months prior to undergoing surgical resection (no later than C6D18 + 14 days).
ARV-471 and EverolimusEXPERIMENTALARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles

Interventions

NameTypeDescription
ARV-471DRUG100 mg tablet
AnastrozoleDRUG1 mg tablet
Surgical resection of breast tumorPROCEDURESurgical resection approximately 5.5 months after starting treatment (C6D18 ± 14 days)
ARV-471 in combination with EverolimusDRUGARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo
Study Sites49

Inclusion Criteria: * Post-menopausal females ≥ 18 years. * Histologically or cytologically confirmed ER+ and HER2- breast cancer (per local assessment). ER and HER2 status must be documented: * ER+ disease, with ER staining of ≥ 10% of tumor cell nuclei by immunohistochemistry (IHC) per America...

Countries:United StatesGeorgiaGermanySpain
Unlock Eligibility Criteria

Competitive Landscape -Breast Cancer 601 trials

Unlock Competitive Intelligence

Frequently asked questions about ARV-471 in combination with Everolimus

What is ARV-471 used for in breast cancer?

ARV-471 is an investigational oral small molecule being studied in breast cancer, including ER-positive, HER2-negative advanced or metastatic disease. It is also being evaluated in post-menopausal women with breast cancer prior to surgery. The combination of ARV-471 with everolimus is specifically under study for advanced or metastatic ER+, HER2- breast cancer.

What does ARV-471 target?

ARV-471 targets the estrogen receptor (ER), a receptor protein that drives growth in many breast cancers. By binding to ER, ARV-471 is designed to degrade the receptor, reducing estrogen signaling that fuels ER-positive tumor cells. This mechanism is being explored in biomarker-selected breast cancer populations.

Who is developing ARV-471?

ARV-471 is being developed by Arvinas, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker ARVN. Arvinas is the sponsor of the clinical trials evaluating ARV-471, including the combination with everolimus in breast cancer.

What phase is ARV-471 in combination with everolimus in?

The combination of ARV-471 with everolimus is in Phase 2 development for breast cancer. A Phase 1 trial of the combination has been completed, and a Phase 2 trial of ARV-471 as a single agent or compared with anastrozole has also been completed. The drug remains investigational and is not approved by the FDA.

What clinical trials is ARV-471 in combination with everolimus in?

ARV-471 in combination with everolimus has been studied in a completed Phase 1 trial, NCT05501769, which enrolled 32 participants with advanced or metastatic ER+, HER2- breast cancer in the United States and Spain. A separate completed Phase 2 trial, NCT05549505, evaluated ARV-471 or anastrozole in post-menopausal women with breast cancer prior to surgery and enrolled 152 participants.